Aptose Announces Results from Annual and Special Meeting of Shareholders
18 juin 2024 17h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03 juin 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market
Under Nasdaq Rules
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31 mai 2024 08h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 mars 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31 janv. 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose closes previously announced public offering and private placement
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 janv. 2024 08h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Reports Results for the Third Quarter 2023
09 nov. 2023 16h00 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Third Quarter 2023
• TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
02 nov. 2023 09h00 HE
|
Aptose Biosciences, Inc.
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
30 oct. 2023 09h15 HE
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
23 oct. 2023 07h30 HE
|
Aptose Biosciences, Inc.
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th